1. Home
  2. ITOC vs IMMP Comparison

ITOC vs IMMP Comparison

Compare ITOC & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ITOC

iTonic Holdings Ltd Class A Ordinary Shares

N/A

Current Price

$2.80

Market Cap

28.1M

Sector

N/A

ML Signal

N/A

Logo Immutep Limited

IMMP

Immutep Limited

BUY

Current Price

$3.18

Market Cap

31.5M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
ITOC
IMMP
Founded
1998
1987
Country
China
Australia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.1M
31.5M
IPO Year
2023
2012

Fundamental Metrics

Financial Performance
Metric
ITOC
IMMP
Price
$2.80
$3.18
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 58.7K
53.7K
Earning Date
03-19-2027
09-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.22
$0.26
52 Week High
$4.49
$5.36

Technical Indicators

Market Signals
Indicator
ITOC
IMMP
Relative Strength Index (RSI) 56.73 58.35
Support Level $0.27 $3.06
Resistance Level $4.49 $5.36
Average True Range (ATR) 0.50 0.21
MACD -0.10 -0.18
Stochastic Oscillator 10.67 9.69

Price Performance

Historical Comparison
ITOC
IMMP

About ITOC iTonic Holdings Ltd Class A Ordinary Shares

iTonic Holdings Ltd through its subsidiary, focuses on healthcare solutions for brachytherapy, a targeted radiation therapy used in cancer treatment. Its product, Beijing Feitian's Treatment Planning System, helps ensure safe and effective brachytherapy using radioactive sources inside the patient to kill cancer cells and shrink tumors. Its product portfolio also includes Medical Auxiliary Supplies such as seed implant needles, computer workstations, patient positioning device, etc.

About IMMP Immutep Limited

Immutep Ltd is a clinical-stage biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: